Medscape (3/27, Melville) reports that even though “guidelines for initiating treatment of symptoms of Alzheimer’s disease (AD) with cholinesterase inhibitors are well established, guidance and consensus as to when, how, and even whether to discontinue the treatment are lacking,” researchers concluded in a presentation given at the American Association for Geriatric Psychiatry’s annual meeting.
Related Links:
— Medscape (requires login and subscription)